Google NewsPro Medicus (ASX:PME) Pulls Back: Is the ASX Healthcare Giant Taking a Pause? - Kalkine
Pro Medicus (ASX:PME) Pulls Back: Is the ASX Healthcare Giant Taking a Pause? Kalkine
PRO MEDICUS LIMITED ORDINARY (PME) News
Latest articles and price-sensitive announcements with AI sentiment classification.
How Is Pro Medicus (ASX:PME) Continuing Its Global Healthcare Technology Expansion? - Kalkine
How Is Pro Medicus (ASX:PME) Continuing Its Global Healthcare Technology Expansion? Kalkine
KalkineWhy Is PME (ASX:PME) Leading Australia's Healthcare Technology Story?
Highlights Pro Medicus remains in focus as demand for medical imaging software continues shaping the healthcare technology landscape. Contract quality, implementation delivery and margin discipline are driving attention across the company's operating model. The market is increasingly rewarding healthcare businesses that demonstrate consistent execution and financial discipline. Pro Medicus remains central to Australia's healthcare sector as...
Pro Medicus (ASX:PME) Shares Move On New AI Cardiology Tie-Up
Highlights Pro Medicus has struck a fresh agreement to broaden its footprint in artificial intelligence-driven cardiology tools. The deal gives the medical imaging software specialist a direct route to resell AI-powered cardiac diagnostic technology across its hospital network. The move builds on Pro Medicus's push into next-generation imaging analytics as demand for AI-assisted diagnostics grows globally. Medical imaging software specialist Pro Medicus Limited (ASX:P...
Why Is PME Setting the Pace for Growth Stocks?
Highlights Pro Medicus is drawing attention as contract durability remains a key quality indicator. Deployment pace and customer retention continue shaping the healthcare software story. Expectation risk remains an important consideration across high-growth companies. Pro Medicus remains a leading healthcare technology company as contract durability, deployment pace and operational discipline continue shaping Australia's evolving Growth Sto...
Why Is Pro Medicus (ASX:PME) A Healthcare Tech Signal?
Highlights Pro Medicus is being assessed through medical imaging software and workflow relevance. CSL and ResMed add wider context across Australian healthcare exposure. ASX healthcare stocks are being filtered through software durability, demand visibility and execution. Pro Medicus frames the ASX healthcare stocks debate as medical imaging software, workflow relevance and peer signals shape a selective evidence-based market screen. ...
PME In Focus As AI Stocks Face A Fresh ASX Test
Highlights Pro Medicus is being watched through clinical workflow automation as the ASX mood stays selective. AI Stocks screens are shifting toward platform trust and hospital workflow relevance instead of broad market excitement. CSL and ResMed add context for readers comparing medical software exposure. PME frames ASX AI as readers assess platform trust and peer signals market context and evidence filters across a selective trading backdrop with fresh practical sect...
Top Reasons Pro Medicus (ASX:PME) Is an AI Healthcare Stock to Watch
Highlights Pro Medicus is drawing attention as clinical workflow automation becomes a key focus across healthcare technology. Market attention has shifted towards platform reliability, recurring demand and execution instead of broad AI enthusiasm. Comparisons with CSL and ResMed highlight how healthcare technology companies are being assessed through operating performance rather than market narratives. Australia's share market is navigating another session...
ASXPME announces appointment Head of Investor Relations
other announcement
Pro Medicus (ASX:PME) Closes Lower: What Investors Are Watching? - Kalkine
Pro Medicus (ASX:PME) Closes Lower: What Investors Are Watching? Kalkine
Can Medicus (ASX:PME) Sustain Momentum After Analyst Price Target Cuts?
Highlights Pro Medicus secured a long-term contract renewal with a leading US medical institution, reinforcing its strong presence in medical imaging software. The healthcare technology company continued to deliver robust earnings and revenue growth, supported by sustained demand across the United States. Despite solid operational performance, market valuation expectations have become more measured as growth stocks undergo a broader reassessment. Australia's share mark...
Pro Medicus (ASX:PME): Why Are Growth Stocks Facing a Health Tech Test?
Highlights ASX growth stocks are drawing attention as health tech compounders return to the market conversation. Pro Medicus, Xero, REA Group and Seek show different signals across software, platforms and digital demand. The focus is on earnings runway proof, operating discipline and credible company updates. ASX growth stocks are drawing attention as health tech compounders build, with Pro Medicus, Xero, REA Group and Seek shaping the earnin...
Why Is Pro Medicus (ASX:PME) Leading the ASX Growth Stocks Conversation?
Highlights ASX growth stocks are being judged more closely on customer retention, earnings quality and business resilience. Pro Medicus, Xero, REA Group and Seek represent different parts of Australia's high-growth corporate landscape. Market attention is shifting from short-term excitement towards sustainable operating performance. ASX growth stocks remain in focus as Pro Medicus, Xero, REA Group and Seek highlight how customer retention, ...
Top Healthcare Stocks to Watch: Why Pro (ASX:PME) Is Leading a New Market Conversation
Highlights Imaging technology and healthcare data platforms are drawing fresh attention as market focus shifts towards operational execution. Pro Medicus (ASX:PME), ResMed (ASX:RMD) and Neuren Pharmaceuticals (ASX:NEU) highlight different strengths across the healthcare sector. Investors are increasingly assessing recurring revenue, customer adoption and implementation discipline instead of short-term market momentum. The Australian share market has entere...
Top Healthcare Growth Stocks to Watch: Pro Medicus (ASX:PME) Leads the Shift
Highlights Healthcare growth rotation is reshaping how growth companies are assessed across the Australian market. Pro Medicus (ASX:PME), ResMed (ASX:RMD), Cochlear (ASX:COH) and Neuren Pharmaceuticals (ASX:NEU) highlight different operational strengths within the healthcare sector. The market is rewarding clinical demand, operational delivery and margin discipline rather than broad sector enthusiasm. Australia's share market is entering the new financial year with a ...
Pro Medicus (ASX:PME): Why Are ASX 200 Growth Stocks Back in Focus?
Highlights Pro Medicus and REA Group have regained market attention after a broad pullback across growth companies. Continued contract activity and business expansion have kept both companies firmly on the market's watchlist. The recent correction has renewed discussion around valuation, business quality and long-term growth. Pro Medicus and REA Group have returned to market focus as business expansion, technology leadership and changing mark...
Why Pro Medicus (ASX:PME) Is Up 11.0% After New US Visage Imaging Contract Wins – And What's Next - simplywall.st
Why Pro Medicus (ASX:PME) Is Up 11.0% After New US Visage Imaging Contract Wins – And What's Next simplywall.st
Why Is Pro Medicus (ASX:PME) Driving the ASX Healthcare Revival?
Highlights Pro Medicus (ASX:PME) strengthened momentum after securing multiple long-term US hospital agreements. A strategic investment and distribution partnership with Echo IQ adds a new growth avenue. Renewed strength across the Healthcare Stocks sector has supported broader market attention. Pro Medicus strengthened its market position through new US...
Why Is Pro Medicus (ASX:PME) Dominating Medical Imaging Software?
Highlights Pro Medicus continues strengthening its presence in the United States through growing adoption of its Visage imaging platform. The company combines strong revenue growth with industry-leading profitability, reinforcing its position in healthcare technology. Demand for advanced diagnostic imaging solutions continues supporting the company's international expansion. Pro Medicus cont...
_10_04_2024_16_38_50_427275.jpg)
Why Is Pro Medicus (ASX:PME) Back in the Spotlight as a Value Stock on the ASX 200?
Highlights Pro Medicus has continued reporting strong business growth despite a sharp decline in its share price. The healthcare software specialist continues expanding through new hospital contracts and recurring revenue. The recent market re-rating has renewed attention on Value Stocks across the Australian market. Pro Medicus has returned to the spotl...
Pro Medicus (ASX:PME): Why Profitable Growth Is Back in Focus
Highlights Profitable growth is becoming the key filter as the Australian market reassesses growth-focused companies. Pro Medicus (ASX:PME), NEXTDC (ASX:NXT), WiseTech Global (ASX:WTC), Lovisa Holdings (ASX:LOV) and Xero (ASX:XRO) highlight different growth drivers across sectors. Strong execution, resilient cash flow and durable margins are drawing more attention than broad sector narratives. Australia's share market is entering a more selective phase wher...
Why Pro Medicus (ASX:PME) Is Refocusing ASX Growth Stocks
Highlights Growth names are entering a quality-first phase as the market demands cleaner business durability. Pro Medicus and NEXTDC frame two different growth stories across healthcare software and digital infrastructure. Current ASX conditions are placing more weight on execution, revenue quality and credible expansion pathways. Growth stocks are entering a quality-first phase as Pro Medic...
Pro Medicus (ASX:PME) Strengthens US Presence Through New Imaging Agreements
Highlights Pro Medicus Ltd (ASX:PME) continues expanding its presence in the United States through new medical imaging agreements and customer renewals. Ongoing contract activity reinforces the company's position within healthcare imaging technology and enterprise software. Market participants remain focused on contract execution, platform adoption and continued expansion across international healthcare networks. Australia's Healthcare Stocks rem...
Why Healthcare Stocks Like Pro Medicus (ASX:PME) And CSL (ASX:CSL) Are Bouncing Back
Highlights Healthcare stocks rebounded strongly as Pro Medicus (ASX:PME), CSL (ASX:CSL) and Ramsay Health Care (ASX:RHC) led sector gains. Echo IQ (ASX:EIQ) secured fresh funding to accelerate its US artificial intelligence healthcare expansion. Biome Australia (ASX:BIO) reported record annual revenue while Memphasys (ASX:MEM) expanded its IVF distribution footprint in Southeast Asia. Healthcare stocks enjoyed one of their strongest monthly recoveries after a prolonge...
_06_30_2026_23_47_38_678990.jpg)
Why Pro Medicus (ASX:PME) Is Splitting Trend Screens?
Highlights Pro Medicus and Megaport appeared among the stronger trend names in the latest ASX scan. Gold and coal names, including Whitehaven Coal and Northern Star Resources, sat on the weaker side of the screen. The latest scan shows a sharper divide between technology momentum and resources pressure. Pro Medicus and Megaport stood out in stronger ASX trend screens, while Whitehaven Coal, ...
Pro Medicus (ASX:PME) in Focus After Echo IQ Partnership and US Contract Renewal
Highlights Pro Medicus (ASX:PME) has entered a strategic partnership with Echo IQ (ASX:EIQ) to broaden its presence in AI-enabled cardiac imaging. The company has renewed a long-term agreement with Allegheny Health Network, highlighting continued demand for its Visage imaging platform. The developments reinforce Pro Medicus' expanding footprint across the global medical imaging software market. Pro Medicus (ASX:PME) has returned to the spotlight following two ...
Why Is Pro Medicus (ASX:PME) Testing Healthcare Stocks?
Highlights Clinical validation is becoming a sharper theme across Australian healthcare names. CSL, Cochlear, ResMed, Pro Medicus and Telix show different parts of the sector. Readers are watching regulatory progress, execution quality and currency movement. ASX healthcare stocks are facing a clinical validation test as regulatory progress, specialist technology and rare-disease updates place ex...
Why Is Pro Medicus (ASX:PME) Driving the Diagnostics Shift in ASX Healthcare Stocks?
Highlights Medical imaging, diagnostics and digital healthcare platforms are reshaping Australia's healthcare sector. Pro Medicus (ASX:PME), CSL (ASX:CSL), Cochlear (ASX:COH), ResMed (ASX:RMD), Telix Pharmaceuticals (ASX:TLX) and Neuren Pharmaceuticals (ASX:NEU) represent different healthcare strengths. Clinical execution, workflow ownership and regulatory progress remain central themes across the sector. ...
Why Is Pro Medicus (ASX:PME) Back in the Growth Spotlight?
Highlights Healthcare proof is becoming a sharper test for ASX growth stocks. Regulatory and commercial milestones are helping separate durable names from hype. Pro Medicus, Telix Pharmaceuticals and REA Group frame the latest growth-stock debate. ASX growth stocks are being tested through healthcare proof, with regulatory progress, commercial milestones and customer retention shaping the latest...
Pro Medicus (ASX:PME) AI Partnership Keeps Healthcare Software Stock In Focus
Highlights Pro Medicus (ASX:PME) strengthened market attention after announcing an artificial intelligence partnership with Echo IQ (ASX:EIQ). The agreement expands Pro Medicus' AI strategy by adding third-party cardiac diagnostic software to its Visage platform. Healthcare technology and artificial intelligence remain major themes shaping Australia's Healthcare Stocks sector. Pro Medicus (ASX:PME) attracted strong market attention af...
ASX Technical Analysis: Why Pro Medicus (ASX:PME), Life360 (ASX:360) and Telix (ASX:TLX) Are Back in Focus
Highlights Technical momentum continues building across selected healthcare, technology and digital growth companies despite mixed broader market conditions. Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Lindian Resources and the Global X Cybersecurity ETF have emerged among the strongest momentum names. Sector rotation continues supporting companies linked to artificial intelligence, cybersecurity, digital healthcare and critical minerals. Australia's ...
Is Pro Medicus (ASX:PME) the Best Quality Tech Stock on the ASX? - Kalkine
Is Pro Medicus (ASX:PME) the Best Quality Tech Stock on the ASX? Kalkine
Pro Medicus (ASX:PME): Is the High-Beta Growth Reset Just Beginning?
Highlights High-beta ASX growth names are facing a fresh test as EOFY positioning gives way to the July market setup. Iress, Pro Medicus, Generation Development Group and Neuren Pharmaceuticals show different angles of the growth reset. The market screen is shifting from headline momentum to profitable growth, valuation discipline and operating evidence. The June quarter close has put ASX growth names back under sharper review, with Pro Medicus (ASX:PME), Ires...
_06_28_2026_23_31_50_220670.jpg)
Why Is Pro Medicus (ASX:PME) in Focus as ASX 200 Opens the Week?
Highlights Mixed global market signals and easing geopolitical tensions are shaping the Australian market outlook. Healthcare emerged as one of the strongest overseas sectors while technology remained under pressure. Pro Medicus, Healius, Horizon Oil and Nine Entertainment headline today's corporate developments. Global market uncertainty, stronger healthcare performance and fresh Australian...
Why Pro Medicus (ASX:PME) Keeps Winning in Health Tech?
Highlights Pro Medicus stands out as a specialist in advanced medical imaging software used by major hospital networks. Its contract-driven model continues to reinforce a strong, recurring revenue structure within global healthcare systems. The company remains a standout name within the ASX mid cap healthcare technology space. Pro Medicus remains a leading healthcare technology name, supported b...
Pro Medicus (ASX:PME) Joins Forces With EchoIQ—Could This Reshape Healthcare AI?
Highlights Pro Medicus has announced a strategic investment and commercial partnership with EchoIQ. The collaboration aims to expand artificial intelligence capabilities within cardiac imaging. The agreement strengthens Pro Medicus' broader strategy of integrating AI into clinical imaging workflows. Pro Medicus Ltd (ASX:PME) has strengthened its artificial intelligence ambitions after announcing a strategic investment and commercial partnership with EchoIQ Ltd...
Pro Medicus (ASX:PME) Hunting for Its Next AI Deal? These ASX Healthcare Stocks Stand Out
Highlights Pro Medicus continues expanding its healthcare AI ecosystem through strategic partnerships. Several ASX-listed medical technology companies have emerged as potential strategic fits. Cardiology, diagnostic imaging and medical AI remain key areas of industry innovation. Pro Medicus Ltd (ASX:PME) has attracted renewed market attention following its recent investment in EchoIQ, adding to its earlier backing of 4DMedical. The latest move has prompted bro...
Motley FoolPro Medicus just struck a revolutionary AI cardiology deal. Here's why that matters
This small-ticket transaction matters far more than its size suggests. The post Pro Medicus just struck a revolutionary AI cardiology deal. Here's why that matters appeared first on The Motley Fool Australia.
Pro Medicus (ASX:PME) and CSL (ASX:CSL): The Healthcare Signal the Market Can’t Ignore
Highlights Diagnostics software and recurring revenue are reshaping how healthcare shares are being assessed across the Australian market. Pro Medicus (ASX:PME), CSL (ASX:CSL), ResMed (ASX:RMD), Telix Pharmaceuticals (ASX:TLX) and 4DMedical (ASX:4DX) are highlighting the growing importance of company-specific execution. Healthcare sector strength is increasingly being linked to cash flow quality, earnings visibility and operational delivery. The Australian sto...
Profitable Growth Bounce Puts Pro Medicus (ASX:PME) in Focus
Highlights Profitable growth is reshaping how the market evaluates growth-focused companies across Australia. Pro Medicus (ASX:PME), Telix Pharmaceuticals (ASX:TLX) and Life360 (ASX:360) are drawing attention as investors focus on execution and business quality. Inflation trends, sector rotation and company-specific catalysts are creating a more selective environment for growth stocks. The Australian share market is entering a period where broad market move...
Is EchoIQ the ASX's Hottest AI Medtech Stock After the Pro Medicus Bombshell? - Kalkine
Is EchoIQ the ASX's Hottest AI Medtech Stock After the Pro Medicus Bombshell? Kalkine
Pro Medicus (ASX:PME) Signs Echo IQ Agreement: What It Means for PME Investors - Kalkine
Pro Medicus (ASX:PME) Signs Echo IQ Agreement: What It Means for PME Investors Kalkine
StockheadHealth Check: For Pro Medicus, lightning strikes twice on another ASX-listed imaging up and comer
Shares in the AI-enabled heart imager have vaulted up to 50%, on the back of a $10-20 million investment from ... Read More The post Health Check: For Pro Medicus, lightning strikes twice on another ASX-listed imaging up and comer appeared first on Stockhead.
Small Caps
Pro Medicus (ASX:PME): Why Is Its Latest AI Move Turning Heads?
Highlights Pro Medicus has announced a strategic agreement with Echo IQ to support the expansion of artificial intelligence capabilities in medical imaging. The agreement combines a capital management initiative with a commercial distribution arrangement for AI-powered cardiac software. The latest development highlights the company's broader strategy of expanding its healthcare technology ecosystem. Australia's healthcare technology sector continues evolving a...
Pro Medicus (ASX:PME) writes a A$20m cheque into Echo IQ - Stocks Down Under
Pro Medicus (ASX:PME) writes a A$20m cheque into Echo IQ Stocks Down Under
Pro Medicus signs Echo IQ deal to boost AI cardiology offering
Pro Medicus has signed a binding agreement with Echo IQ to boost its AI-driven cardiology solutions and expand commercial opportunities. The post Pro Medicus signs Echo IQ deal to boost AI cardiology offering appeared first on The Motley Fool Australia.
PME signs HoA Echo IQ Finance Facility & Reseller Agreement
other announcement
Pro Medicus (ASX:PME): The Contract Signal Reshaping Healthcare Stocks
Highlights Medical imaging software contracts are becoming a key measure for assessing healthcare sector momentum amid shifting market conditions. Pro Medicus (ASX:PME), CSL (ASX:CSL) and Cochlear (ASX:COH) highlight how execution, cash flow quality and market expectations are driving stock-specific narratives. US contract wins and index-related fund flows are increasingly influencing how healthcare stocks are being interpreted across the Australian market. Th...
Pro Medicus (ASX:PME): The Insider Signal Changing How Growth Stocks Are Judged
Highlights Founder and insider alignment is becoming a key measure for assessing growth companies in a more selective market environment. Pro Medicus (ASX:PME), Life360 (ASX:360) and Lovisa Holdings (ASX:LOV) highlight how execution, cash flow quality and governance are shaping market sentiment. Growth companies are increasingly being judged on evidence of sustainable expansion rather than broad sector themes. The Australian share market is entering a phase wh...
Pro Medicus (ASX:PME): Why Profitable Growth Is the Market’s New Test
Highlights Growth stocks are increasingly being judged on margin strength and cash-flow quality rather than revenue growth alone. Pro Medicus (ASX:PME), Life360 (ASX:360) and Lovisa Holdings (ASX:LOV) highlight how execution is shaping market attention across different sectors. Rising macro uncertainty and selective market sentiment are making profitable growth one of the most closely watched themes in Australian equities. The Australian share market is ent...
Pro Medicus (ASX:PME) Is Up 5.4% After Record Half-Year And A$280m Contracts Has The Bull Case Changed? - simplywall.st
Pro Medicus (ASX:PME) Is Up 5.4% After Record Half-Year And A$280m Contracts Has The Bull Case Changed? simplywall.st
Why Pro Medicus (ASX:PME) and Telix Are Driving Healthcare Buzz
Highlights Specialist imaging and radiopharmaceutical businesses are attracting renewed attention across the Australian healthcare sector. Pro Medicus (ASX:PME), Telix Pharmaceuticals (ASX:TLX) and Cochlear (ASX:COH) remain key names linked to clinical adoption and healthcare technology trends. Market focus is shifting towards operating performance, contract quality, cash generation and sustainable growth signals. Australia's equity market is navigating a complex backdrop of geopolitical unce...
Pro Medicus (ASX:PME): The Premium ASX Tech-Healthcare Stock Everyone Watches - Kalkine
Pro Medicus (ASX:PME): The Premium ASX Tech-Healthcare Stock Everyone Watches Kalkine
Pro Medicus (ASX:PME), Wesfarmers (ASX:WES) or IVV: Which Option Stands Out for a Small ASX Start?
Highlights A modest starting amount can provide exposure to global markets, healthcare technology and diversified Australian businesses. Pro Medicus, Wesfarmers and the iShares S&P 500 ETF each offer access to different growth and resilience themes. Diversification and quality remain important considerations when building a portfolio over time. Pro Medicus, Wesfarmers and the iShares S&P 500 ETF provide different pathways to healthcare technology, diversified Australian businesses and...
Pro Medicus shares are flying 35% higher. Time to cash out?
Big rally fuels debate: hold, buy, or sell? The post Pro Medicus shares are flying 35% higher. Time to cash out? appeared first on The Motley Fool Australia.
Is Pro Medicus (ASX:PME) a Strong Buy Signal for ASX Health-Tech?
Highlights Pro Medicus (ASX:PME) gains renewed attention after appearing on a Strong Buy themed ASX tech list. Debt-free balance sheet and strong cash position reinforce its financial resilience. Global expansion of its Visage imaging platform supports continued healthcare software demand. Pro Medicus (ASX:PME) remains in focus as a leading health-tech company, supported by a debt-free balance sheet and expanding global adoption of its medical imaging software. Australian healthcare tec...
Pro Medicus (ASX:PME): Why This Global Healthcare Leader Is Drawing Fresh Attention
Highlights Intuitive Surgical’s recent weakness has reignited discussion around healthcare technology business models. Companies with recurring revenue streams continue attracting attention amid evolving healthcare trends. Australian healthcare leaders such as Pro Medicus, ResMed and Nanosonics remain closely watched for their scalable business models. Healthcare technology companies remain in focus as recurring revenue models, digital healthcare adoption and artificial intelligence con...
Is Pro Medicus (ASX:PME) Worth Adding to Your Watchlist? - Kalkine
Is Pro Medicus (ASX:PME) Worth Adding to Your Watchlist? Kalkine
Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation
Highlights Growth stocks are facing a tougher quality test as investors focus on earnings upgrades and pricing power. Pro Medicus, REA Group, and ResMed are emerging as key reference points across the growth sector. Balance-sheet strength and operational execution are becoming more important than broad market enthusiasm. Australian growth stocks are facing a more demanding quality test as earnings upgrades, pricing power, and operational execution become increasingly important drivers o...